Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANRONASDAQ:INZYNASDAQ:QNCXNASDAQ:QNTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANROAlto Neuroscience$1.86-9.5%$3.23$1.83▼$17.55$50.22M2.14361,446 shs324,161 shsINZYInozyme Pharma$0.88-5.5%$1.19$0.82▼$7.31$59.51M1.39488,117 shs388,310 shsQNCXQuince Therapeutics$1.26-4.5%$1.44$0.51▼$2.45$55.44M0.71243,655 shs130,882 shsQNTMQuantum Biopharma$7.86-2.2%$6.55$2.70▼$18.00$15.08M0.371.18 million shs236,338 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANROAlto Neuroscience-9.95%-23.19%-40.45%-59.76%-86.92%INZYInozyme Pharma-5.49%-11.98%-21.83%-71.48%-87.79%QNCXQuince Therapeutics-4.55%-10.00%-14.29%-35.38%+20.00%QNTMQuantum Biopharma-2.24%-6.21%+86.26%+96.01%+785,999,900.00%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANROAlto Neuroscience0.9187 of 5 stars3.30.00.00.00.00.00.6INZYInozyme Pharma3.0076 of 5 stars4.53.00.00.00.62.50.6QNCXQuince Therapeutics2.305 of 5 stars3.62.00.00.01.90.81.3QNTMQuantum BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANROAlto Neuroscience 2.50Moderate Buy$16.75802.96% UpsideINZYInozyme Pharma 3.00Buy$14.561,562.54% UpsideQNCXQuince Therapeutics 3.29Buy$8.00534.92% UpsideQNTMQuantum Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest QNTM, ANRO, QNCX, and INZY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $4.003/24/2025QNCXQuince TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$10.003/21/2025ANROAlto NeuroscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/12/2025INZYInozyme PharmaRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$24.00 ➝ $12.003/11/2025INZYInozyme PharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$30.00 ➝ $23.003/11/2025INZYInozyme PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/11/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$23.00 ➝ $15.003/10/2025INZYInozyme PharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.00 ➝ $7.002/5/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.001/13/2025INZYInozyme PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$14.00 ➝ $11.001/13/2025INZYInozyme PharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$43.00 ➝ $30.00(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANROAlto NeuroscienceN/AN/AN/AN/AN/AN/AINZYInozyme PharmaN/AN/AN/AN/A$2.27 per shareN/AQNCXQuince TherapeuticsN/AN/AN/AN/A$1.98 per shareN/AQNTMQuantum BiopharmaN/AN/AN/AN/A$21.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANROAlto Neuroscience-$36.31M-$2.54N/AN/AN/AN/A-49.28%-33.52%5/13/2025 (Estimated)INZYInozyme Pharma-$71.17M-$1.63N/AN/AN/AN/A-88.42%-57.02%5/6/2025 (Estimated)QNCXQuince Therapeutics-$31.39M-$1.31N/AN/AN/AN/A-53.27%-22.73%4/7/2025 (Estimated)QNTMQuantum Biopharma-$17.90M-$15.70N/AN/AN/AN/A-84.21%-62.63%5/13/2025 (Estimated)Latest QNTM, ANRO, QNCX, and INZY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/7/2025N/AQNCXQuince Therapeutics-$0.10N/AN/AN/AN/AN/A3/28/2025Q4 2024QNTMQuantum Biopharma-$0.80-$2.89-$2.09-$2.89$0.92 millionN/A3/24/2025Q4 2024QNCXQuince Therapeutics-$0.19-$0.28-$0.09-$0.28N/A$0.17 million3/20/2025Q4 2024ANROAlto Neuroscience-$0.65-$0.56+$0.09-$0.56N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANROAlto NeuroscienceN/AN/AN/AN/AN/AINZYInozyme PharmaN/AN/AN/AN/AN/AQNCXQuince TherapeuticsN/AN/AN/AN/AN/AQNTMQuantum BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANROAlto Neuroscience0.0513.1013.09INZYInozyme Pharma0.517.687.68QNCXQuince Therapeutics0.339.539.53QNTMQuantum BiopharmaN/A3.763.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANROAlto NeuroscienceN/AINZYInozyme Pharma88.30%QNCXQuince Therapeutics30.75%QNTMQuantum Biopharma1.24%Insider OwnershipCompanyInsider OwnershipANROAlto NeuroscienceN/AINZYInozyme Pharma11.19%QNCXQuince Therapeutics16.80%QNTMQuantum Biopharma8.53%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANROAlto NeuroscienceN/A27.07 millionN/AN/AINZYInozyme Pharma5064.24 million57.05 millionOptionableQNCXQuince Therapeutics6044.00 million36.61 millionOptionableQNTMQuantum BiopharmaN/A1.92 million1.76 millionN/AQNTM, ANRO, QNCX, and INZY HeadlinesRecent News About These CompaniesQuantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto RicoApril 3 at 7:00 AM | globenewswire.comBest Cannabis Stocks To Watch Now - March 30thApril 1 at 2:03 AM | americanbankingnews.comQuantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple SclerosisApril 1 at 2:00 AM | globenewswire.comQuantum Biopharma Announces Closing of Final $2.42 Million Tranche of $5 Million Total Financing on Improved TermsMarch 31, 2025 | globenewswire.comTop Cannabis Stocks To Follow Today - March 28thMarch 31, 2025 | americanbankingnews.comCannabis Stocks To Follow Today - March 29thMarch 31, 2025 | americanbankingnews.comQuantum BioPharma reports progress in drug trialsMarch 30, 2025 | uk.investing.comQuantum BioPharma Provides Corporate UpdateMarch 30, 2025 | newsfilecorp.comQuantum BioPharma reports FY24 net loss $14.9M vs. $18.2M last yearMarch 28, 2025 | markets.businessinsider.comOverlooked Stock: QNTMMarch 28, 2025 | youtube.comQuantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going ConcernMarch 28, 2025 | accessnewswire.comQuantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going ConcernMarch 28, 2025 | globenewswire.comCannabis Stocks To Consider - March 26thMarch 28, 2025 | americanbankingnews.comQuantum Group announces licensee expands unbuzzd lineupMarch 26, 2025 | markets.businessinsider.comQuantum BioPharma Licensee Celly Nutrition Expands unbuzzd™ Alcohol Detox Product Lineup for Retail SalesMarch 26, 2025 | markets.businessinsider.comQuantum BioPharma Stock Soars After Licensee Celly Nutrition Releases New Format Of Alcohol Detox Product – Retail Shrugs It OffMarch 26, 2025 | msn.comQuantum BioPharma Continues to Grow Its Crypto Assets and Diversify Its Treasury With the Purchase of Another USD $1,500,000 Worth of Bitcoin (BTC) and Other CryptocurrenciesMarch 20, 2025 | globenewswire.comQuantum BioPharma Unaware of Any Material ChangeMarch 17, 2025 | newsfilecorp.comQuantum BioPharma Provides Corporate UpdateMarch 7, 2025 | newsfilecorp.comQuantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302February 26, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQNTM, ANRO, QNCX, and INZY Company DescriptionsAlto Neuroscience NYSE:ANRO$1.86 -0.20 (-9.51%) Closing price 04/3/2025 03:58 PM EasternExtended Trading$1.83 -0.02 (-1.29%) As of 06:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.Inozyme Pharma NASDAQ:INZY$0.88 -0.05 (-5.49%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$0.86 -0.02 (-2.23%) As of 07:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Quince Therapeutics NASDAQ:QNCX$1.26 -0.06 (-4.55%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$1.22 -0.04 (-3.57%) As of 07:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.Quantum Biopharma NASDAQ:QNTM$7.86 -0.18 (-2.24%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$7.56 -0.30 (-3.75%) As of 07:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Celsius Heats Up: Acquisition, Analyst Upgrade Fuel Momentum 5 Reasons Why Halliburton Is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Equinix: A Smart Bet on Data Centers, Dividends, and AI Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
